,i  #aaith ,,congress  #ast ,session    
,h4 ,r4 #acdi  ,,in ,,the ,,house ,,of  
,,representatives  ,february #ac1       
#bjbe,mr4 ,steube 7for himself1 ,ms4    
,tenney1 ,mr4 ,haridopolos1 ,mr4        
,mc,guire1 and ,mr4 ,biggs of ,arizona7 
introduced the following bill2 which was
 referred to the ,committee on ,ways and
 ,means1 and in addition to the         
,committee on ,energy and ,commerce1 for
 a period to be subsequently determined 
by the ,speaker1 in each case for       
consideration of such provisions as fall
 within the jurisdiction of the         
committee concerned  ,a ,,bill  ,to     
amend title ,,xi of the ,social         
,security ,act to exclude providers of  
certain abortion services from          
participation in the ,medicare program4 
#a4 ,short title ,this ,act may be cited
 as the ,women's ,protection in         
,telehealth ,act4  #b4 ,excluding       
providers of certain abortion services  
from participation in the ,medicare     
program ,section #aabh of the ,social   

,security ,act 7#db ,u4,s4,c4           
#acbj;a-#g7 is amended--  7#a7 in       
subsection 7a7-- 7,a7 in the matter     
preceding paragraph 7#a71 by inserting  
7or1 in the case of individuals and     
entities described in paragraph 7#e71   
from participation in the ,medicare     
program under title ,,xviii7 after 7as  
defined in section #aabh;,b7f772 and    
7,b7 by inserting after paragraph 7#d7  
the following new paragraph3  7#e7      
,provision of abortion-inducing drugs   
,any individual or entity that1 on or   
after the date of the enactment of this 
paragraph1 prescribes1 administers1     
dispenses1 or furnishes an              
abortion-inducing drug to a patient1    
unless such individual or entity--  7,a7
 is a physician2  7,b7 physically       
examines the patient2  7,c7 is          
physically present in the same room with
 the patient at the time the patient is 
administered1 takes1 or uses 7as        
applicable7 such drug2 and  7,d7        
schedules an in-person follow-up visit  

for the patient to occur not more than  
#ad days after the patient is           
administered1 takes1 or uses 7as        
applicable7 such drug4  2 and  7#b7 in  
subsection 7c77#c7-- 7,a7 in            
subparagraph 7,a71 by striking          
subsection 7b77#ab7 and inserting       
subsection 7a77#e7 or 7b77#ab72  7,b7 in
 subparagraph 7,b71 by striking         
subparagraph 7,g7 and inserting         
subparagraphs 7,g7 and 7,h72  7,c7 in   
subparagraph 7,g71 by inserting 7other  
than under paragraph 7#e7 of such       
subsection7 after subsection 7a72 and   
7,d7 by adding at the end the following 
new subparagraph3  7,h7 ,in the case of 
an exclusion under subsection 7a77#e71  
the exclusion shall be permanent4  2    
7#c7 in subsection 7d71 by adding at the
 end the following new paragraph3  7#d7 
,the provisions of this subsection shall
 not apply in the case of an exclusion  
under subsection 7a77#e74  2  7#d7 in   
subsection 7g71 by adding at the end the
 following new paragraph3  7#d7 ,the    

provisions of this subsection shall not 
apply in the case of an exclusion under 
subsection 7a77#e74  2 and  7#e7 by     
adding at the end the following new     
subsection3  7k7 ,abortion-,inducing    
drug defined  7#a7 ,in general ,for     
purposes of subsection 7a71 the term    
abortion-inducing drug means any        
medicine1 drug1 or any other substance  
that is prescribed1 administered1       
dispensed1 or furnished with the intent 
of terminating the clinically           
diagnosable pregnancy of a woman and    
with knowledge that the termination will
 with reasonable likelihood cause the   
death of the unborn child 7including the
 off-label use of any such drug74  7#b7 
,unborn child ,the term unborn child has
 the meaning given such term in section 
#ahda of title #ah1 ,united ,states     
,code4  4